Series s cm5 chip

Manufactured by GE Healthcare

Sourced in United States

The Series S CM5 chip is a diagnostic lab equipment component designed to perform core functions within a larger analytical system. The chip is engineered to enable precise data processing and analysis capabilities required for various laboratory applications. Its specific features and intended uses are not included in this factual, unbiased description.

Automatically generated - may contain errors

Lab products found in correlation

9 protocols using series s cm5 chip

Affinity Measurements of 2C1 Fynomer and IL-17A

Check if the same lab product or an alternative is used in the 5 most similar protocols

Affinity measurements were performed using a BIAcore T200 instrument (GE Healthcare). For the interaction analysis between 2C1 monomer and IL-17A, a Series S CM5 chip (GE Healthcare) was coated with 2000 Resonance Units of IL-17A immobilized using the amine coupling kit (GE Healthcare). The running buffer was PBS containing 0.05% Tween 20. The interactions were measured at a flow of 30 μl/min and injection of different concentrations of Fynomer 2C1 (highest concentration, 100 nm and subsequent 3-fold dilution series). All kinetic data of the interaction were evaluated using the BIAcore T200 evaluation software. Similarly, for the interaction analysis between 2C1-Fc fusions and IL-17A, a Series S CM5 chip was coated with 500 Resonance Units of IL-17A immobilized using the amine coupling kit (GE Healthcare). The interactions were measured at a flow of 30 μl/min (PBS containing 0.05% Tween 20) and injection of different concentrations of 2C1-Fc fusions (highest concentration: 50 nm and subsequent 2-fold dilution series). All kinetic data of the interaction were evaluated using the BIAcore T200 evaluation software.

Silacci M., Baenziger-Tobler N., Lembke W., Zha W., Batey S., Bertschinger J, & Grabulovski D. (2014). Linker Length Matters, Fynomer-Fc Fusion with an Optimized Linker Displaying Picomolar IL-17A Inhibition Potency. The Journal of Biological Chemistry, 289(20), 14392-14398.

+ Open protocol

+ Expand

Gold Nanoparticle-Based Biosensor Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

Chloroauric acid, sodium tetrahydroborate, and trisodium citrate dehydrate were purchased from Sinopharm Chemical Reagent. HEWL, RNase A, and BSA were obtained from Sigma-Aldrich. sEGFR and EGF were obtained from Creative BioMart. Cetuximab was obtained from Shanghai TheraMabs Biotech. Mouse anti-EGFR/Cy5 was obtained from Bioss Antibodies. Tri-N-acetyl-d-glucosamine was obtained from Aladdin Reagent. FITC-PEG [polyethylene glycol; molecular weight (MW) 5K]-SH was obtained from Qian-Bi Bio-Tech (Shanghai). Peptides were synthesized by GL Biochem. N-hydroxysuccinimide, N-ethyl-N-(3-diethylaminopropyl) carbodiimide hydrochloride, ethanolamine⋅HCl (1 M solution, pH 8.5), HBS-EP buffer [10 mM Hepes, 150 mM NaCl, 3 mM EDTA, 0.05% (vol/vol) surfactant P20, pH 7.4], and series S CM5 chips were obtained from GE Healthcare. Ultrapure Millipore water was used. All other chemicals were of analytical grade.

Yan G.H., Wang K., Shao Z., Luo L., Song Z.M., Chen J., Jin R., Deng X., Wang H., Cao Z., Liu Y, & Cao A. (2017). Artificial antibody created by conformational reconstruction of the complementary-determining region on gold nanoparticles. Proceedings of the National Academy of Sciences of the United States of America, 115(1), E34-E43.

+ Open protocol

+ Expand

Kinetic Analysis of CA-II Inhibitor Binding

Check if the same lab product or an alternative is used in the 5 most similar protocols

The CA-II binding experiment was performed on a Biacore T200 SPR instrument. Series S CM5 chips containing carboxymethylated dextran (GE Healthcare) were used for all measurements. CA-II protein was immobilized using amine coupling chemistry at room temperature. PBS-P+ (pH 7.4, containing 0.5% surfactant P20) buffer was used as immobilization buffer. Using a flow rate of 10 μL/min, the chip surface was activated with a 7 min injection of 0.4 M EDC and 0.1 M NHS, followed by 7 min injection of 100 μg/mL CA-II protein in 10 mM sodium acetate (pH 5.0). Unreacted NHS groups were blocked with 7 min injection of ethanolamine. As a result, CA-II was immobilized on the chip to 6000 response unit. One flow cell of the chip was left as a reference surface without protein immobilization.
For kinetic analysis, 3% DMSO in PBS-P+ was used as running buffer. Inhibitor 1 was 2-fold diluted from 2.0 μM to 0.125 μM and injected for 50 seconds at a flow rate of 30 μL/min and dissociation was monitored for 3 minutes. Each cycle of analyte injection was followed by a 1 minute injection of running buffer as a washing step. Data sets were blank correlated and analyzed with the Biacore T200 evaluation software using a 1:1 binding model.

Zhou X., Su X., Pathak P., Vik R., Vinciguerra B., Isaacs L, & Jayawickramarajah J. (2017). Host-Guest Tethered DNA Transducer: ATP Fueled Release of a Protein Inhibitor from Cucurbit[7]uril. Journal of the American Chemical Society, 139(39), 13916-13921.

+ Open protocol

+ Expand

CTLA-4 Ectodomain Binding Affinity

Check if the same lab product or an alternative is used in the 5 most similar protocols

All experiments were performed with a Biacore T100 SPR system (GE Healthcare) at 25°C in HBS-EP buffer [10 mmol/L HEPES, pH 7.4, 150 mmol/L NaCl, 3.4 mmol/L edetic acid, 0.005% (v/v) surfactant P20]. Recombinant IgG antibodies were immobilized on Series S CM5 chips (GE Healthcare) and soluble ectodomains of recombinant human CTLA-4 were injected to the flow cells at different concentrations. Background binding to blank immobilized flow cells was subtracted and affinity constants were calculated using BIAcore T100 evaluation software (GE Healthcare) using the 1:1 Langmuir binding model.

Knorr D.A., Blanchard L., Leidner R.S., Jensen S.M., Meng R., Jones A., Ballesteros-Merino C., Bell R.B., Baez M., Marino A., Sprott D., Bifulco C.B., Piening B., Dahan R., Osorio J.C., Fox B.A, & Ravetch J.V. (2023). FcγRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment. Cancer Immunology Research, 12(3), 322-333.

+ Open protocol

+ Expand

SPR Analysis of DLD-Rg3 Interaction

Check if the same lab product or an alternative is used in the 5 most similar protocols

In this study, a Biacore T200 optical biosensor (GE Healthcare, USA) was used for the surface plasmon resonance (SPR) experiment. Series S CM5 chips (GE Healthcare, USA) were selected as coupling chips. Ethanolamine HCl, EDC, NHS, caps, and sampling vials were all purchased from Biacore (GE Healthcare, USA). The running buffer was PBS buffer contains 5% DMSO. The recombinant DLD wild-type and mutant proteins (about 50 mg/mL) were coupled to a CM5 chip with approximately 7000 RU coupling amount for each channel. Then the diluted Rg3 (0–300 μM) was flowed through the chips at 30 μL/min. The solvent correction was performed at the same time, and the data were collected and analyzed in the Biacore T200 evaluation software.

Ni J., Zhang H., Wang X., Liu Z., Nie T., Li L., Su J., Zhu Y., Ma C., Huang Y., Mao J., Gao X, & Fan G. (2022). Rg3 regulates myocardial pyruvate metabolism via P300-mediated dihydrolipoamide dehydrogenase 2-hydroxyisobutyrylation in TAC-induced cardiac hypertrophy. Cell Death & Disease, 13(12), 1073.

+ Open protocol

+ Expand

Kinetic Evaluation of FOLR1 Binding

Check if the same lab product or an alternative is used in the 5 most similar protocols

Biacore T100 (GE Healthcare, Buckinghamshire, England) was used to evaluate the binding affinity to FOLR1-His. A Human Antibody Capture Kit (GE Healthcare) was immobilized onto a Series S CM5 chip (GE Healthcare) by amine coupling. Subsequently, KHK2805 or KM8188 was captured on the chip. FOLR1-His prepared for 5-step dilution (12.3, 37, 111, 333 and 1000 ng/mL) by HBS-EP+ buffer (GE Healthcare) was then applied as an analyte. Kinetic constants (ka, kd, KD) were calculated by a 1:1 binding model in single-cycle kinetics using the Biacore T100 Evaluation software program (GE Healthcare).

Ando M., Nagata K., Nihira K., Suzuki Y., Kanda Y., Adachi M., Kubota T., Kameyama N., Nakano M., Ando H., Yamano K., Ishii T., Nakai R, & Nakamura K. (2017). Potent Therapeutic Activity Against Peritoneal Dissemination and Malignant Ascites by the Novel Anti-Folate Receptor Alpha Antibody KHK2805. Translational Oncology, 10(5), 707-718.

+ Open protocol

+ Expand

Kinetic Analysis of Anti-PfCyRPA mAb Binding

Check if the same lab product or an alternative is used in the 5 most similar protocols

Experiments were performed at 25°C in the HBS-EP+ running buffer (GE Healthcare). Approximately 400 RU of active mAb was amine-coupled to a Series S CM5 chip (GE Healthcare) on Fc 2 (CyP1.9) and Fc 3 (CyP2.38) using standard NHS/EDC chemistry. The dual injection mode was used at a flow-rate of 20 µL/min to first inject 25 nM of recombinant PfCyRPA for 180 sec, directly followed by an injection of anti-PfCyRPA mAb at 30 nM for 180 sec over all flow cells. This was followed by a dissociation time of 180 sec and a regeneration step using 10 mM glycine-HCl pH 1.5 (GE Healthcare) for 5-20 sec, depending on the mAb immobilized on the chip. All data generated was subtracted by the reference flow cell (Fc 1) and blank runs with running buffer.

Knudsen A.S., Björnsson K.H., Bassi M.R., Walker M.R., Kok A., Cristinoi B., Jensen A.R, & Barfod L. (2021). Strain-Dependent Inhibition of Erythrocyte Invasion by Monoclonal Antibodies Against Plasmodium falciparum CyRPA. Frontiers in Immunology, 12, 716305.

+ Open protocol

+ Expand

Thrombin-Protein Binding Kinetics via SPR

Check if the same lab product or an alternative is used in the 5 most similar protocols

Surface plasmon resonance (SPR)-based interaction analysis of the sample protein and thrombin was performed using a Biacore 8K instrument (GE Healthcare, Wauwatosa, WI, USA). Sample protein was diluted to 10 µg/mL in 10 mM sodium acetate (pH 4.0) and injected over 420 s at 10 µL/min with approximately 5,000–6,000 RU. Sample protein was immobilized via amine coupling to a series S CM5 chip (GE, USA). Thrombin was diluted in running buffer (PBS, 0.05% P20 (GE, USA)).
Thrombin plated in a 9-point dose response with a compound concentration of 0 as a reference, and the highest compound concentration used was 10 µM (run parameters: 30 µL/min, high-performance injection and data collection at 10 Hz, temperature at 250 °C, association time of 120 s and dissociation time of 600 s). Binding curves are shown, and the affinity constants (K_D values) were calculated by BIA evaluation 4.1 software.

Cheng B., Liu F., Guo Q., Lu Y., Shi H., Ding A, & Xu C. (2019). Identification and characterization of hirudin-HN, a new thrombin inhibitor, from the salivary glands of Hirudo nipponia. PeerJ, 7, e7716.

+ Open protocol

+ Expand

Surface Plasmon Resonance Analysis of Ligand-Receptor Binding

Check if the same lab product or an alternative is used in the 5 most similar protocols

SPR experiments were performed on a BIAcore T200 instrument at 37°C in filtered buffer HBS-P pH 7.4. Proteins (rhDLL4 and rhJAG1) were immobilized on a Series S CM5 chip (GE Healthcare) using GE Healthcare's amine coupling kit. Reference flow channels underwent a cycle of activation and deactivation but were left empty. Serial dilutions of FPLC purified monomeric rhgal/ rhgal3C in HBS-P buffer were used as analyte, with or without addition of 50 mM lactose or 50mM sucrose. Curve fitting was performed in GraphPad Prism 6.0.
The number of exposed gal-3 binding sites per immobilized molecule of JAG1 or DLL4 was calculated using the equation:

b i n d i n g s s i t e s p e r i m m o b i l i z e d m o l e c u l e = \frac{R U_{\max} / M W_{a n a l y t e}}{R U_{immobilized} / M W_{l i g a n d}}

(Where RU_max is the maximum binding and MW is molecular weight) [63 (link)].

dos Santos S.N., Sheldon H., Pereira J.X., Paluch C., Bridges E.M., El-Cheikh M.C., Harris A.L, & Bernardes E.S. (2017). Galectin-3 acts as an angiogenic switch to induce tumor angiogenesis via Jagged-1/Notch activation. Oncotarget, 8(30), 49484-49501.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!